Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Karl Keirstead

UBS Started Coverage of CoreWeave With a ‘Buy’ Rating. What This Means for CRWV Stock.

UBS started coverage of CoreWeave with a Buy rating and a $120 target on Sept. 23, arguing the market is underestimating demand for AI computing capacity.

Barchart · Sep 28

Analysts Warn of ‘Substantial Risks’ for Palantir Stock Ahead of May 5

Palantir is expected to double its per-share earnings to $0.08 in Q1. Still, a UBS analyst warns of downside risk in PLTR shares ahead of May 5.

Barchart · Apr 29, 2025

Bearish on the Market? 2 Defensive Stocks for Maximum Portfolio Protection.

As economic growth is anticipated to slow, UBS highlights these two dividend-paying defensive stocks as smart picks, shifting focus away from cyclical stocks.

Barchart · Dec 26, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Today: Stocks Struggle in Post-Christmas Session

Stocks were choppy in Thursday's low-volume session.

Kiplinger · Dec 26, 2024

What Analysts Are Saying About Oracle Stock

Oracle (NYSE:ORCL) has been analyzed by 31 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga · Dec 5, 2024

Oracle Stock Soars on OpenAI, Google Deals, Strong Outlook

Oracle stock is trading higher as the software firm's new AI deals and upbeat outlook offset an earnings miss. Here's what you need to know.

Kiplinger · Jun 12, 2024

Here's What Analysts Had To Say About GitLab Post Q1 Beat

Analysts acknowledged GitLab Inc's (NASDAQ:GTLB) Q1 beat by re-rating the stock. RBC Capital analyst Matthew Hedberg maintained GitLab with an Outperform and raised the price target from $64 to $66. GitLab reported a solid start to the year as execution continued in its third quarter as a public company, Hedberg noted. Revenue growth again accelerated while RPO…

Benzinga · Jun 7, 2022

Read news from The Economist, FT, and more,
with one subscription

Here's Why UBS Is Cautious On Microsoft, Alibaba

UBS painted a cautious picture of Microsoft Corp (NASDAQ: MSFT) and Alibaba Group Holding Ltd (NYSE: BABA).

Benzinga · Apr 11, 2022

Why MongoDB Shares Are Rising

MongoDB Inc (NASDAQ: MDB) shares are trading higher Friday following bullish analyst coverage from UBS. UBS analyst Karl Keirstead upgraded MongoDB from a Neutral rating to a Buy rating and raised the price target from $345 to $450.

Benzinga · Mar 18, 2022

UBS Bumps Up MongoDB Price Target By 30%

UBS analyst Karl Keirstead upgraded MongoDB Inc (NASDAQ:MDB) to Buy from Neutral with a price target of $450, up from $345 (20.8% upside). Channel checks suggested MongoDB benefits directly from the mega-trend to build new applications using a micro-services architecture, solidifying his view that MongoDB is a "play on the apps modernization mega-trend." The shares…

Benzinga · Mar 18, 2022

Read How Analysts Reacted To Salesforce's Q4 Results

Analysts adjusted their price targets on Salesforce.com Inc (NYSE:CRM) post Q4 results. Citi analyst Tyler Radke raised the firm's price target on Salesforce to $233 from $220 (11.5% upside) and kept a Neutral. The company "delivered a reassuring" Q4 and outlook, which should help alleviate concerns around the health of the front office and general…

Benzinga · Mar 2, 2022

Here's How Analysts View Zoom Ahead Of Its Quarterly Results

Analysts revised their price targets on Zoom Video Communications Inc (NASDAQ:ZM) ahead of its quarterly results. UBS analyst Karl Keirstead lowered the price target on Zoom to $130 from $250 (8% upside) and kept a Neutral rating on the shares ahead of its quarterly results. Despite the 35% year-to-date decline in the stock, the analyst recommends…

Benzinga · Feb 24, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations